Year-to-date global revenues are up 5 percent and 7 percent higher year-over-year in the U.S. for Brooks Running as the Seattle-based company has reached new runners, recovered from Covid-19-related supply chain disruptions, and normalized inventory levels. Crediting the strong September launch of its Ghost Max style, Brooks is confident it will achieve double-digit sales growth in 2024. The brand’s U.S. e-commerce sales are up 25 percent year-to-date.

According to Upper Quadrant Specialty Run market data, Brooks currently has five of the top 10 selling running shoes in the U.S. specialty run channel. The brand also owned a 21.4 percent market share in the U.S. retail adult performance running shoe market, achieving the top spot in the segment for a seventh consecutive period in Q3, according to Circana’s retail tracking service.

In January, Brooks will introduce the Glycerin 21, the next generation of the fan favorite, featuring additional DNA LOFT v3 cushioning, and debut the Hyperion Elite 4 distance racing shoe ahead of the 2024 U.S. Olympic Marathon Team Trials in February. Also in early 2024, the brand will make its new 3D-printed midsole technology, 3DNA, available in limited quantities in the Exhilarate-BL to members of its loyalty program.